Pharmaceutical Technology

DECEMBER 10, 2024

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia - is forecast to grow from $582m in 2020 to $6.2bn in 2030 at a compound annual growth rate of 26.7%, with the paediatric and adult segments (..)

Compounding 59

Compounding 59

Drug Patent Watch

DECEMBER 10, 2024

billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% from 2023 to 2030. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

Drug Development 96

Drug Development Communication Pharmaceutical Companies Pharmaceutical Companies 96

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. This represents a compound annual growth rate (CAGR) of close to 10 percent. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review.

Dosage 52

Dosage Compounding 52

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Labelling 59

Labelling Compounding 59

Express Pharma

MARCH 20, 2025

GlobalDatas report, Endometriosis Market Size and Trend Report, reveals that the endometriosis market size across the seven major markets* (7MM) is expected to achieve a compound annual growth rate of more than 9 per cent during 2020-2030.

Dosage 66

Dosage Compounding Hospitals 66

Express Pharma

SEPTEMBER 19, 2023

billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 per cent from 2021 to 2030. The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01

Chemotherapy 105

Chemotherapy Compounding 105

Express Pharma

MAY 30, 2024

billion in 2030, with a compound annual growth rate (CAGR) of 117.6 The sales of Otsuka’s Rexulti in Japan are expected to increase from $114 million in 2023 to $556 million in 2030, with a CAGR of 25.5 Comparatively, Leqembi and Rexulti exhibit CAGRs of 134.1 per cent and 25.5 per cent and 108.6 per cent, respectively.

Compounding 115

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 115

Safe Biologics

JUNE 12, 2023

By 2030, colorectal cancer is predicted to become the leading cause of cancer deaths for people under 50, and is already the second leading cause of all cancer deaths, behind only lung cancer. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

By 2030, colorectal cancer is predicted to become the leading cause of cancer deaths for people under 50, and is already the second leading cause of all cancer deaths, behind only lung cancer. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

European Pharmaceutical Review

JULY 24, 2023

A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. It requests that compounding laboratories adhering to the programme send samples of it. PACMI selects a drug on a quarterly basis.

Compounding 93

Compounding Documentation Drug Development 93

European Pharmaceutical Review

FEBRUARY 3, 2023

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review.

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

SEPTEMBER 15, 2023

With a compound annual growth rate (CAGR) of 6.76 percent, the global market of Dercum’s disease treatment in 2030 is predicted to grow to $19.95 Promisingly, Caliway also shared that according to the Global Dercum’s Disease Market Research Report, the global Dercum’s disease treatment market size in 2021 was $11.3

Compounding 119

Compounding 119

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. percent between 2022-2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Peak sales are anticipated to reach $1.3

Labelling 98

Labelling Compounding 98

pharmaphorum

AUGUST 2, 2022

The potential for ADCs to combine the best of both mAbs and small molecule drugs means that there has been high interest in developing a successful compound since the first successful clinical trial in 1983. Development of the compound was subsequently ended. Looking to the future. Not all rosy.

Compounding 98

Compounding Drug Development 98

Express Pharma

JANUARY 11, 2024

The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8 Canakinumb, set for a 2030 launch, is a biosimilar to the established Ilaris therapy. per cent from $4.6 billion in 2022 to $10.8

Biosimilars 103

Biosimilars Compounding 103

Express Pharma

JANUARY 2, 2025

million by 2030. Lyophilization is a crucial process in preserving the stability and shelf life of pharmaceutical products, especially for sensitive chemical compounds. The global lyophilized injectables market, estimated at a value of approximately $ 3,365.4 With a CAGR of 5.6

Dosage 52

Dosage Compounding 52

Express Pharma

JUNE 7, 2024

billion by 2030, at a compound annual growth rate (CAGR) of 4.7 The main treatments for MS focus on slowing the disease’s progression and are disease-modifying therapies (DMTs). According to GlobalData’s forecast on the multiple sclerosis market size, it is expected that sales for MS DMTs will grow to $30.1 per cent during 2020 -30.

Compounding 80

Compounding 80

Express Pharma

AUGUST 17, 2023

Globally, the systemic antibacterial market, which is growing at a compounded annual growth rate of 4.26 per cent, is set to reach $60 billion by year 2030. It is awaiting marketing authorisation for the drug from another 16 countries.

Compounding 98

Compounding 98

pharmaphorum

JULY 27, 2022

AmerisourceBergen notes that the US market for DTx is predicted to grow at a compound annual growth rate of nearly 25% between 2022 to 2030, according to figures from Grand View Research which valued the category at $4.2 billion in 2021.

Medical Records 72

Medical Records Compounding 72

Express Pharma

MARCH 22, 2024

billion by 2030. This slow response mechanism further compounds issues Report merging delays: After trials, coordinating for reports across departments becomes a herculean task, delaying the final report dispatch to patrons. By 2020, out of the mammoth $200 billion pumped into pharma research, a whopping $48.4

Compounding 105

Compounding 105

Safe Biologics

JUNE 12, 2023

By 2030, colorectal cancer is predicted to become the leading cause of cancer deaths for people under 50, and is already the second leading cause of all cancer deaths, behind only lung cancer. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

pharmaphorum

MAY 12, 2022

These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down. Compounds that modulate the activity of these enzymes have potential in oncology, for example, in blood cancers like multiple myeloma. billion partnership last week. .

Compounding 52

Compounding 52

PharmD Live

MAY 13, 2024

Their projections indicate that approximately 10,000 people will turn 65 each day over the next 19 years, with the population of older adults expected to double to 80 million by 2030. At this rate, nearly half of the older population could be impacted by polypharmacy by 2030. Data from the U.S. in 1994 to 42.4%

Long-Term Care Facilities 105

Long-Term Care Facilities Diabetes Nursing Homes Prescription Filling 105

European Pharmaceutical Review

DECEMBER 21, 2022

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. In the context of CO 2 neutrality, the years 2030 and 2050 are mentioned as crucial milestones.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

epicur

AUGUST 8, 2023

Implementation of GFI #256 Earlier this year, the FDA finalized regulatory guidance for compounded medications, known as GFI #256. If GFI is affecting your practice’s ability to get compounded medications for office use, partnering with a trusted 503B outsourcing facility can help you eliminate risks of limited ordering.

Compounding 52

Compounding Documentation Compounding Pharmacies Packaging 52

Safe Biologics

JUNE 12, 2023

By 2030, colorectal cancer is predicted to become the leading cause of cancer deaths for people under 50, and is already the second leading cause of all cancer deaths, behind only lung cancer. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Express Pharma

MARCH 21, 2024

From dissecting market trends to envisioning future in near (2030) and long-term (2047), vriddhi 2024 provided a platform for everyone to engage, collaborate, and chart a course towards sustainable growth. Currently valued at $50 billion, the industry is divided equally between export and domestic markets.

Compounding 104

Compounding Pharmaceutical Companies Pharmaceutical Companies 104

Quality Matters

MARCH 1, 2024

USP has a long-standing history of healthcare standards including those for compounding preparations that are tailored to meet the unique needs of patients who may not otherwise have access to their medications. market by 2030, and this growth is not limited to the U.S., in the U.S.

Labelling 52

Labelling Compounding 52

Express Pharma

MARCH 25, 2025

The global cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate of 44 per cent, with sales projected to rise from $8.70 billion in 2030. The post Cell and gene therapy market set to grow at 44% CAGR through 2030: GlobalData appeared first on Express Pharma. billion in 2024 to $76.03

Compounding 66

Compounding 66

Express Pharma

JULY 10, 2024

Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million.

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7 LXE408 is currently entering Phase II clinical development.

Vaccines 110

Vaccines Communication Documentation Compounding 110

European Pharmaceutical Review

AUGUST 19, 2022

percent compound annual growth rate (CAGR) of the market include the increasing commercialisation of generics and emerging technologies and small biotechs with limited or no production capabilities driving development in the biopharmaceutical sector. billion by 2026. The market was valued at approximately $100 billion in 2020.

Packaging 98

Packaging Compounding 98

Pharmaceutical Technology

MAY 18, 2023

The World Health Organization (WHO) 2021 roadmap outlines plans to eradicate 20 listed diseases, which include leprosy, scabies and mycetoma, by 2030. Neglected tropical diseases are a major global health concern, affecting over 1.7 billion people, many of whom live in the poorest and most vulnerable communities.

Vaccines 52

Vaccines Compounding 52

Express Pharma

MAY 25, 2024

India’s pharmaceutical industry is on a promising path, with a vision to reach a staggering $130 billion by 2030 and $450 billion by 2047, according to a report by Ernst and Young. This growth is fueled by a thriving pharma industry that has already exported over 300 million vaccine doses as of July 2023 and impressive growth with $668.9

Compounding 59

Compounding Vaccines 59

Express Pharma

OCTOBER 16, 2024

The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 billion by 2030 (2). Courtesy of contract research organisations (CROs), contract manufacturing organisations (CMOs), and contract development and manufacturing organisations (CDMOs), India’s life sciences sector is rising steadily. per cent, hitting $44.63

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

PharmaShots

APRIL 3, 2023

The P-III trial (GUARD) results showed no safety signals & were found to be well tolerated with no observed treatment-emergent serious AEs ADX-2191 is a sterile, non-compounded IVT formulation of methotrexate for specific rare retinal diseases. old, for use by women with diabetes who are pregnant & for wear time of up to 15 days.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40